Vernakalant (RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic. Vernakalant is shown to have good conversion rates, an apparently safe antiarrhythmic profile and is well tolerated in patients with a history of ischemic heart disease.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.
Blomström-Lundqvist C, et al. Expert Opin Drug Saf. 2012 Jul;11(4):671-9. PMID: 22632377.
|Related Potassium Channel Products|
2,2,2-Trichloroethanol is an agonist for the nonclassical K2P channels TREK-1 (KCNK2) and TRAAK (KCNK4).
Nigericin is an antibiotic derived from Streptomyces hygroscopicus, it acts as an H+, K+, Pb2+ ionophore.
ML213 (CID-3111211) is a selective KV7.2 (KCNQ2) and KV7.4 (KCNQ4) channel opener, with EC50 values of 230 and 510 nM for KV7.2 and KV7.4, respectively.
CLP290 is a novel, orally available KCC2 modulator, highly selective for KCC2 over related Cl- transporters.
BMS-191011 is a potent BKCa channel opener (large-conductance Ca2+-activated potassium channel, KCa1.1).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.